Market Research Logo

Premature Ejaculation - Pipeline Review, H2 2015

Premature Ejaculation - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Premature Ejaculation - Pipeline Review, H2 2015’, provides an overview of the Premature Ejaculation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Premature Ejaculation Overview
Therapeutics Development
Pipeline Products for Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics under Development by Companies
Premature Ejaculation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Premature Ejaculation - Products under Development by Companies
Premature Ejaculation - Companies Involved in Therapeutics Development
Allergan Plc
NeuroHealing Pharmaceuticals Inc.
Plethora Solutions Holdings Plc
SK Chemicals Co., Ltd.
Premature Ejaculation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles (lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(tramadol hydrochloride + PDE-5 Inhibitor) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IX-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE-405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tramadol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premature Ejaculation - Recent Pipeline Updates
Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: Vyrix Pharmaceuticals to Present at Biotech Showcase 2015
Nov 11, 2014: Plethora Solutions Provides Company Update
Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
Mar 11, 2014: Plethora Solutions Provides Company update
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
Jun 03, 2013: Ampio Pharma Provides Update On Sexual Dysfunction Portfolio
Mar 11, 2013: Ampio Receives FDA Acceptance Of Patient Outcome For Premature Ejaculation Questionnaire Paving Way For US Pivotal Trial On Zertane
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Premature Ejaculation, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Premature Ejaculation - Pipeline by Allergan Plc, H2 2015
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2015
Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H2 2015
Premature Ejaculation - Pipeline by SK Chemicals Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Premature Ejaculation Therapeutics - Recent Pipeline Updates, H2 2015
Premature Ejaculation - Dormant Projects, H2 2015
Premature Ejaculation - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Premature Ejaculation, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report